
CEL-SCI Corporation (&#34;CEL-SCI&#34; or the &#34;Company&#34;) (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an

<p xmlns="http://www.w3.org/1999/xhtml">
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CVM">CVM</a>), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company intends to use the proceeds for the continued development of Multikine&#x2A;, general corporate purposes, and working capital.

</p><p xmlns="http://www.w3.org/1999/xhtml">
ThinkEquity is acting as the sole placement agent for the offering.

</p><p xmlns="http://www.w3.org/1999/xhtml">
A registration statement on Form S-1 (File No. 333-295168) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on May 11, 2026. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41<sup xmlns="http://www.w3.org/1999/xhtml">st</sup> Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at <span xmlns="http://www.w3.org/1999/xhtml" class="bwuline"><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54533970&amp;newsitemid=20260511186764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.sec.gov&amp;index=1&amp;md5=748946d630b648cac51a4537cf191388" shape="rect">http://www.sec.gov</a></span>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About CEL-SCI Corporation</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system &#34;target&#34; the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words &#34;intends,&#34; &#34;believes,&#34; &#34;anticipated,&#34; &#34;plans&#34; and &#34;expects,&#34; and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company&#39;s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI&#39;s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">&#x2A; Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company&#39;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</i>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260511186764r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260511186764/en/" rel="nofollow">https://www.businesswire.com/news/home/20260511186764/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
COMPANY CONTACT:
<br xmlns="http://www.w3.org/1999/xhtml"></br>Gavin de Windt
<br xmlns="http://www.w3.org/1999/xhtml"></br>CEL-SCI Corporation
<br xmlns="http://www.w3.org/1999/xhtml"></br>(703) 506-9460

</p>

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI announces $7.2 million stock offering to fund Multikine development

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CEL-SCI Corporation (&amp;#34;CEL-SCI&amp;#34; or the &amp;#34;Company&amp;#34;) (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>CEL-SCI Corporation has announced a public offering of 6 million shares priced at $1.20 each, aiming to raise approximately $7.2 million. These funds will support the development of Multikine and other corporate needs, with the offering set to close on May 13, 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CVM priced a public offering of 6 million shares at $1.20 each.</li><li>Expected gross proceeds are approximately $7.2 million for operations.</li><li>Proceeds will fund Multikine development and general corporate purposes.</li><li>The offering closure is anticipated on May 13, 2026, pending conditions.</li><li>ThinkEquity is the sole placement agent for this offering.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ThinkEquity</strong>: Acting as the sole placement agent for this share offering.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments as it relates to CVM&#039;s financial maneuvers for operational funding. The successful capital raise is vital for ongoing clinical trials and overall company strategy.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CVM&#039;s ability to raise effective capital during a public offering is critical for its plans.</li><li>Success in developing Multikine could potentially boost stock value and investor confidence.</li><li>Regulatory approvals for Multikine are crucial and could influence future offerings.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Offering includes 6 million shares at $1.20 each.</li><li>Expected to raise $7.2 million before fees and expenses.</li><li>Scheduled offering closure on May 13, 2026.</li><li>The Multikine product targets squamous cell carcinoma and received Orphan Drug designation.</li><li>Over 740 patients have been dosed with Multikine in clinical studies.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors may consider CVM a buy due to funding for clinical development and stock pricing.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CVM">CVM</a>), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company intends to use the proceeds for the continued development of Multikine&#x2A;, general corporate purposes, and working capital.

</p><p xmlns="http://www.w3.org/1999/xhtml">
ThinkEquity is acting as the sole placement agent for the offering.

</p><p xmlns="http://www.w3.org/1999/xhtml">
A registration statement on Form S-1 (File No. 333-295168) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on May 11, 2026. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41<sup xmlns="http://www.w3.org/1999/xhtml">st</sup> Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at <span xmlns="http://www.w3.org/1999/xhtml" class="bwuline"><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54533970&amp;newsitemid=20260511186764&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.sec.gov&amp;index=1&amp;md5=748946d630b648cac51a4537cf191388" shape="rect">http://www.sec.gov</a></span>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About CEL-SCI Corporation</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system &#34;target&#34; the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words &#34;intends,&#34; &#34;believes,&#34; &#34;anticipated,&#34; &#34;plans&#34; and &#34;expects,&#34; and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company&#39;s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI&#39;s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">&#x2A; Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company&#39;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</i>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260511186764r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260511186764/en/" rel="nofollow">https://www.businesswire.com/news/home/20260511186764/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
COMPANY CONTACT:
<br xmlns="http://www.w3.org/1999/xhtml"></br>Gavin de Windt
<br xmlns="http://www.w3.org/1999/xhtml"></br>CEL-SCI Corporation
<br xmlns="http://www.w3.org/1999/xhtml"></br>(703) 506-9460

</p>

CEL-SCI Corporation has announced a public offering of 6 million shares priced at $1.20 each, aiming to raise approximately $7.2 million. These funds will support the development of Multikine and other corporate needs, with the offering set to close on May 13, 2026.

CEL-SCI Corporation Announces Pricing of Public Offering

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News